Kisspeptin
Kisspeptin-10
- Injection
- Oral
- Nasal spray
- Suppository
- Gel or cream
Injection — protocol not established.
No provider we've verified carries Kisspeptin yet
Kisspeptin is a neuropeptide encoded by the KISS1 gene. It sits upstream of nearly every signal that drives human reproduction — telling GnRH neurons when and how often to fire. Without it, puberty doesn’t happen. People with loss-of-function mutations in the kisspeptin receptor never enter puberty without exogenous hormone replacement, a finding that rearranged reproductive endocrinology when it was identified in 2003.
What makes kisspeptin different from other reproductive peptides is positional. GnRH executes the signal; kisspeptin tells GnRH when to fire. It binds KISS1R, a G-protein-coupled receptor on GnRH neurons, triggering a calcium cascade that depolarizes the cell. The neuron fires, GnRH gets released, the pituitary responds with LH and FSH, and the gonads produce testosterone, estradiol, and gametes. The biology is unusually clean for a neuropeptide. The clinical picture is messier — kisspeptin has real human trial data, a clear mechanism, and zero approved products.
Kisspeptin is the timekeeper of the reproductive axis — the signal that tells the rest of the system when to start. It has real human data and no approved product anywhere.
Who it's for (or who should avoid)
What it's aimed at
Kisspeptin protocols are most commonly studied for:
- Hypogonadotropic hypogonadism — restoring LH and FSH in patients whose defect sits upstream of GnRH
- Fertility support — IVF triggering, particularly for women at high risk of ovarian hyperstimulation syndrome
- Sexual wellness — psychosexual processing and desire, studied in both men and women with hypoactive sexual desire disorder
- Diagnostic use — provocative testing to distinguish hypothalamic, pituitary, and gonadal lesions in reproductive endocrine workups
- Hypothalamic amenorrhea — restoring menstrual cycles in women whose reproductive axis has shut down due to stress, undernutrition, or overtraining
It works best as part of a broader reproductive or endocrine plan — alongside imaging, hormone panels, and a defined clinical goal — rather than as a standalone intervention.
Who should avoid it
- Anyone pregnant, breastfeeding, or planning a pregnancy in the near term — pregnancy safety data at therapeutic doses is unknown
- People with a history of ovarian hyperstimulation syndrome or at high risk for it — kisspeptin’s role in IVF triggering is still being defined
- Patients whose reproductive axis lesion sits at or below the GnRH neuron itself — kisspeptin won’t bypass a pituitary or gonadal defect
- Anyone on continuous GnRH agonist therapy — the two signals could interact unpredictably
Kisspeptin works with your endocrine system, not instead of it. The most robust data so far comes from single-dose or short-duration infusion protocols; long-term efficacy and safety in repeated-dosing regimens are still being mapped.
Route, dose and course
Kisspeptin is most commonly administered as an intravenous infusion in research settings. The native peptide (kisspeptin-54) has a plasma half-life of about 28 minutes, so protocols typically use controlled infusion rates rather than bolus injections.
Protocols clinicians and researchers commonly use:
- Standard research dose: 1 nmol/kg/h IV infusion over 75 minutes for psychosexual and neuroendocrine studies
- Fertility protocols: single-dose or short-duration infusions timed to oocyte maturation windows in IVF cycles
- Diagnostic use: kisspeptin challenge tests to measure LH and FSH response curves
- Investigational analogs: MVT-602 (TAK-448), a longer-acting synthetic agonist, has been tested in Phase 1/2 trials with a delayed LH peak at ~21 hours versus ~5 hours for native kisspeptin-54
Because kisspeptin is investigational and not commercially available, dosing occurs under IND authorization in a research setting, against a protocol rather than a prescription. Nothing above is a dose to act on: there is no product to buy, and no clinician outside a trial is in a position to write one.
The usual arc
Read this first. Individual response varies. Most research protocols use single-dose or short-duration infusions; long-term response patterns in repeated-dosing protocols are still being mapped.
Kisspeptin is investigational, and most human data comes from single-dose research rather than long protocols. Any response is best judged with a clinician tracking the relevant hormones, not by feel alone. The arc below reflects what the research describes so far.
- SINGLE DOSEAcute hormonal responseLH and FSH rise within minutes in most participants. The response is dose-dependent and typically peaks within the first hour.
- WEEK 1–4Short-duration protocolsMost published trials use single-dose or short infusion windows. Repeated-dosing data in humans is still building.
- ONGOINGLong-term patterns unknownWhether the LH response is maintained, attenuates, or requires pulsed dosing over months is an open research question.
No provider we've verified carries Kisspeptin yet
That is the honest answer, and it is not the same as "you can't have it". None of the licensed telehealth providers we track publishes Kisspeptin, so there is no price to quote and no intake to send you to. Whether that changes depends on federal action rather than on us — which is why the next box exists rather than a button that goes nowhere.
Tell me when someone carries it
Questions we get about Kisspeptin
Is kisspeptin FDA-approved?
No — kisspeptin is investigational and not approved for any indication. Clinical use occurs under IND authorization in research settings. There's no FDA drug label, and it's not available at retail pharmacies.
Is it legal?
Kisspeptin can be administered to research participants under appropriate regulatory authorization at institutions with active INDs. Outside that framework, it's not a fielded therapeutic. Kisspeptin-10 sits on the FDA's 503A Category 2 list (substances that raise significant safety risks), so it's not available through the standard compounded-peptide channel. There is no provider to check with, in any state: the route runs through a research institution with an active IND or it does not exist.
See what licensed providers actually carry →Are there side effects?
In published infusion studies, reported side effects have been mild: injection-site reactions, transient nausea, occasional headache, mild flushing tied to the acute LH surge. No cardiovascular events were reported in the trial literature. Long-term safety data in repeated-dosing protocols is still being gathered.
Can I take it with my current medications?
Kisspeptin's interaction profile with other medications is not fully characterized outside research settings. If you're considering participation in a kisspeptin trial, disclose your full medication list — including supplements and hormone therapies — to the research team.
How much does it cost?
Because kisspeptin is investigational and not commercially available, there's no standard pricing. Participation in clinical trials is typically at no cost to the participant. If a compounded version becomes available in the future, pricing would depend on the formulation and source pharmacy.
We publish no medical reviewer by design. Every claim on this page traces to a source we hold on file, and the reviewed write-up with those citations lives on our hub. Read the full research on PeptideWellness ↗
Fuel your protocol with
the latest research + reviews
Independent updates on peptide therapy, breaking news from compounding pharmacies, and exclusive guides — straight to your inbox.
